2023 Volume 12 Issue 3 Pages 161-166
CD36 antigen is expressed on various cell types, including platelets and monocytes, but individuals who lack CD36 expression only on platelets (type Ⅱ deficiency) and on all cell types (type Ⅰ deficiency) exist, and type Ⅰ deficient individuals may produce CD36 antibody through antigenic stimulation. CD36-deficiency is rare in Caucasian, but more frequently found in Asian and African. CD36 antibodies are involved in the pathophysiology of various immune-mediated clinical conditions, such as platelet transfusion refractoriness (PTR) and fetal-neonatal alloimmune thrombocytopenia (FNAIT). CD36 expression has also been confirmed on cells of the erythroblasts and myeloblasts, but presently little is known on role of CD36 antigen/antibodies in allogeneic stem cell transplantation (ASCT). Here, we provide an overview of the clinical implications and the present knowledge related to CD36 antigen/antibody in ASCT.
